BCL-W has a fundamental role in B cell survival and lymphomagenesis

Journal of Clinical Investigation

Volumn 127, Issue 2, 2017, Pages 635-650

  Adams, Clare M ^a   Kim, Annette S ^b   Mitra, Ramkrishna ^a   Choi, John K ^c   Gong, Jerald Z ^a   Eischen, Christine M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 15A; PROTEIN BCL W; BCL2L2 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; PROTEIN;

3T3 CELL LINE; ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOID TISSUE; LYMPHOMAGENESIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, KNOCKOUT; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 85014095348     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89486     Document Type: Article

References (60)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674.
2. Hata AN, Engelman JA, Faber AC. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. 2015;5(5):475-487.
3. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5(10):1024-1039.
4. Adams JM, et al. The c-MYC oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538.
5. Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99-109.
6. Gibson L, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene. 1996;13(4):665-675.
7. O'Reilly LA, et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ. 2001;8(5):486-494.
8. Print CG, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA. 1998;95(21):12424-12431.
9. Ross AJ, et al. Testicular degeneration in Bclwdeficient mice. Nat Genet. 1998;18(3):251-256.
10. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene. 2009;28(9):1274-1279.
11. Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res. 2003;63(5):1093-1100.
12. Wilson JW, et al. Bcl-w expression in colorectal adenocarcinoma. Br J Cancer. 2000;82(1):178-185.
13. Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC, Pellecchia M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2010;1:e40.
14. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995;23(10):1686-1690.
15. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-MYC transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
16. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in MYC-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669.
17. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL. Bax loss impairs MYC-induced apoptosis and circumvents the selection of p53 mutations during MYC-mediated lymphomagenesis. Mol Cell Biol. 2001;21(22):7653-7662.
18. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of MYC-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101(16):6164-6169.
19. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304-317.
20. Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by MYC-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21(15):5063-5070.
21. Eischen CM, et al. Bcl-2 is an apoptotic target suppressed by both c-MYC and E2F-1. Oncogene. 2001;20(48):6983-6993.
22. Adams CM, Eischen CM. Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma. Cell Death Differ. 2016;23(8):1312-1321.
23. Adams CM, Hiebert SW, Eischen CM. MYC induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res. 2016;76(3):736-748.
24. Eilers M, Eisenman RN. MYC's broad reach. Genes Dev. 2008;22(20):2755-2766.
25. Herold S, et al. Negative regulation of the mammalian UV response by MYC through association with Miz-1. Mol Cell. 2002;10(3):509-521.
26. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
27. Yang X, et al. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep. 2012;27(1):250-257.
28. Yin KJ, et al. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis. 2010;38(1):17-26.
29. Yang T, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol. 2015;36(6):4357-4365.
30. Chang TC, et al. Widespread microRNA repression by MYC contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50.
31. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2): a014282 .
32. Kelly GL, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28(1):58-70.
33. Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM. Endogenous Bcl-xL is essential for MYC-driven lymphomagenesis in mice. Blood. 2011;118(24):6380-6386.
34. Kelly PN, Puthalakath H, Adams JM, Strasser A. Endogenous bcl-2 is not required for the development of Emu-MYC-induced B-cell lymphoma. Blood. 2007;109(11):4907-4913.
35. Michalak EM, et al. Puma and to a lesser extent Noxa are suppressors of MYC-induced lymphomagenesis. Cell Death Differ. 2009;16(5):684-696.
36. Garrison SP, et al. Selection against PUMA gene expression in MYC-driven B-cell lymphomagenesis. Mol Cell Biol. 2008;28(17):5391-5402.
37. Zindy F, et al. MYC signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424-2433.
38. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54(8):2095-2097.
39. Sugars KL, Budhram-Mahadeo V, Packham G, Latchman DS. A minimal Bcl-x promoter is activated by Brn-3a and repressed by p53. Nucleic Acids Res. 2001;29(22):4530-4540.
40. Bui TV, Mendell JT. MYC: Maestro of microRNAs. Genes Cancer. 2010;1(6):568-575.
41. Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis. Cell Rep. 2016;14(10):2337-2347.
42. Mérino D, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012;119(24):5807-5816.
43. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121.
44. Al-Harbi S, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 2011;118(13):3579-3590.
45. Tahir SK, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67(3):1176-1183.
46. Whitecross KF, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009;113(9):1982-1991.
47. Mason KD, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive MYC-driven lymphomas. Proc Natl Acad Sci USA. 2008;105(46):17961-17966.
48. Thieblemont C, Brière J. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? Blood. 2013;121(12):2165-2166.
49. Arrate MP, Vincent T, Odvody J, Kar R, Jones SN, Eischen CM. MicroRNA biogenesis is required for MYC-induced B-cell lymphoma development and survival. Cancer Res. 2010;70(14):6083-6092.
50. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits MYC-induced lymphomagenesis. EMBO J. 2003;22(6):1442-1450.
51. Meerbrey KL, et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci USA. 2011;108(9):3665-3670.
52. Adams CM, Eischen CM. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer. Cancer Res. 2014;74(14):3923-3934.
53. Wang P, Lushnikova T, Odvody J, Greiner TC, Jones SN, Eischen CM. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene. 2008;27(11):1590-1598.
54. McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM. miR-223 regulates cell growth and targets proto-oncogenes in MYCosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(4):1101-1107.
55. Wang X, Spandidos A, Wang H, Seed B. PrimerBank: A PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 2012;40(Database issue):D1144-D1149.
56. Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Meth Enzymol. 2006;411:352-369.
57. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127.
59. Lenz G, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
60. Visco C, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B cell lymphoma: A report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-2113.